March 01, 2013
Sun Pharmaceutical Industries Ltd. urged a District of Columbia federal judge Friday to block the U.S. Food and Drug Administration from approving any generic versions of the oncology drug Zometa until the agency decides whether to grant 180-day market exclusivity to the Indian drugmaker.